CLINICAL_TRIALS
withdrawal
· 2017-04-20
Clinical Trial Update: Study of FTY720 in Patients With Uveitis [Phase 2]
Summary
A Phase 2 study of FTY720 (fingolimod) in acute noninfectious uveitis has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Acute Noninfectious Posterior, Intermediate, or Pan Uveitis | Phase 2 | Status: WITHDRAWN